Successful combination therapy for patients with platinum-resistant ovarian cancer

被引：0
|
作者：
不详
机构：
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2008年 / 8卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 7
页数：1
相关论文
共 50 条
  • [31] Defying platinum resistance: Boosting overall survival in platinum-resistant ovarian cancer patients
    Piver, Rachael
    Chesler, Kyle
    Rubin, Lily
    Mysona, David
    Suhner, Jessa
    Ghamande, Sharad
    Johnson, Marian
    Rungruang, Bunja
    Higgins, Robert
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S75 - S76
  • [32] Does early treatment with platinum improve survival in patients with platinum-resistant ovarian cancer?
    Stany, M. P.
    Bidus, M. A.
    Dainty, L. A.
    Krivak, T. C.
    McHale, M. T.
    Winter, W. E.
    Tedjarati, S. S.
    Bieber, A.
    Berek, J. S.
    Rose, G. S.
    Elkas, J. C.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S125 - S126
  • [33] Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
    Pectasides, D
    Psyrri, A
    Pectasides, M
    Economopoulos, T
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (08) : 975 - 987
  • [34] Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
    Pchejetski, Dmitri
    Alfraidi, Albandri
    Sacco, Keith
    Alshaker, Heba
    Muhammad, Aun
    Monzon, Leonardo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (08) : 1659 - 1671
  • [35] Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
    Murakami, Ryusuke
    Hamanishi, Junzo
    Brown, J. B.
    Abiko, Kaoru
    Yamanoi, Koji
    Taki, Mana
    Hosoe, Yuko
    Yamaguchi, Ken
    Baba, Tsukasa
    Matsumura, Noriomi
    Konishi, Ikuo
    Mandai, Masaki
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [36] Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
    Dmitri Pchejetski
    Albandri Alfraidi
    Keith Sacco
    Heba Alshaker
    Aun Muhammad
    Leonardo Monzon
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 1659 - 1671
  • [37] Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer.
    Shah, Payal D.
    Zarrin, Haley
    Wethington, Stephanie
    Latif, Nawar
    Martin, Lainie
    Rodriguez, Diego
    Elkins, Katie
    Giuntoli, Robert
    Burger, Robert
    Tanyi, Janos
    Morgan, Mark
    Domchek, Susan M.
    Gailliard, Stephanie
    Armstrong, Deborah K.
    Simpkins, Fiona
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 75 - 75
  • [38] Combination immune checkpoint blockade and MEK inhibition in a platinum-resistant ovarian cancer model
    Hartnett, E. G.
    Edwards, R. P.
    Vlad, A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 53 - 54
  • [39] Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
    Ryusuke Murakami
    Junzo Hamanishi
    J. B. Brown
    Kaoru Abiko
    Koji Yamanoi
    Mana Taki
    Yuko Hosoe
    Ken Yamaguchi
    Tsukasa Baba
    Noriomi Matsumura
    Ikuo Konishi
    Masaki Mandai
    Scientific Reports, 11
  • [40] An evaluation of the combination of metformin and Y15 for the treatment of platinum-resistant ovarian cancer
    Duarte, Manuel A.
    Garcia, Kristal
    Arriaga, Marco A.
    Chew, Sue Anne
    Levy, Arkene S.
    Mendez, Isabela
    CANCER RESEARCH, 2024, 84 (06)
12345